Human Genome Epidemiology Literature Finder
Records 1 - 7 (of 7 Records) |
Query Trace: Disease Progression and EML4[original query] |
---|
Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer. Breast cancer research and treatment 2012 Jul 134 (2): 561-7. Grob Tobias J, Heilenkötter Uwe, Geist Stefan, Paluchowski Peter, Wilke Christian, Jaenicke Fritz, Quaas Alexander, Wilczak Waldemar, Choschzick Matthias, Sauter Guido, Lebeau Annet |
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. Clinical lung cancer 2015 Dec . Ulivi Paola, Chiadini Elisa, Dazzi Claudio, Dubini Alessandra, Costantini Matteo, Medri Laura, Puccetti Maurizio, Capelli Laura, Calistri Daniele, Verlicchi Alberto, Gamboni Alessandro, Papi Maximilian, Mariotti Marita, De Luigi Nicoletta, Scarpi Emanuela, Bravaccini Sara, Turolla Gian Michele, Amadori Dino, Crinò Lucio, Delmonte Ange |
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 3 14 (7): 1233-1243. Camidge D Ross, Dziadziuszko Rafal, Peters Solange, Mok Tony, Noe Johannes, Nowicka Malgorzata, Gadgeel Shirish M, Cheema Parneet, Pavlakis Nick, de Marinis Filippo, Cho Byoung Chul, Zhang Li, Moro-Sibilot Denis, Liu Ting, Bordogna Walter, Balas Bogdana, Müller Barbara, Shaw Alice |
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. EBioMedicine 2020 Nov 62 103103. Dietz Steffen, Christopoulos Petros, Yuan Zhao, Angeles Arlou Kristina, Gu Lisa, Volckmar Anna-Lena, Ogrodnik Simon J, Janke Florian, Fratte Chiara Dalle, Zemojtel Tomasz, Schneider Marc A, Kazdal Daniel, Endris Volker, Meister Michael, Muley Thomas, Cecchin Erika, Reck Martin, Schlesner Matthias, Thomas Michael, Stenzinger Albrecht, Sültmann Holg |
Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency. Clinical lung cancer 2021 1 22 (4): e519-e527. Bustamante Alvarez Jean G, Janse Sarah, Owen Dwight H, Kiourtsis Stephanie, Bertino Erin M, He Kai, Carbone David P, Otterson Gregory |
Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced nonsmall-cell lung cancer patients with ALK fusion in China. International journal of cancer 2022 5 152 (1): 15-23. Su Chunxia, Zhou Juan, Qiang Huiping, Zhao Jing, Chang Qing, Ji Xianxiu, Li Jiaqi, Xie Mengqing, Chu Tianqi |
Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib. Translational cancer research 2022 2 8 (4): 1630-1634. Zhu You-Cai, Wan Bing, Wu Li-Xin, Li Xing-Liang, Wang Wen-Xian, Xu Chun-Wei, Zhuang Wu, Wei Jian-Guo, Du Kai- |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 29, 2024
- Content source: